Navigation Links
Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease

DUBLIN, October 28 /PRNewswire-FirstCall/ --

- FOSRENOL(R) (lanthanum carbonate) Now Approved in the EU to Treat hyperphosphataemia >1.78mmol/L in Chronic Kidney Disease Patients Not on Dialysis

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced it has received approval through the European Mutual Recognition Procedure for an extension to the current indication for FOSRENOL(R) (lanthanum carbonate), paving the way to make the non-calcium, non-resin phosphate binder available throughout the EU to control hyperphosphataemia in chronic kidney disease (CKD) patients who are not on dialysis with a serum phosphorus level greather than or equal to 1.78mmol/L (5.5mg/dL).

The extension was sanctioned by the Swedish Medicines Products Agency as reference member state. Submissions for national marketing authorizations have been made to Sweden and the other 28 European markets with first national approvals anticipated in Q4 2009.

"Failure to control phosphate in the earlier stages of chronic kidney disease carries well documented risks, and is associated with reduced bone health and poor cardiovascular outcomes," said Dr. Alastair Hutchison, Manchester Royal Infirmary, UK. "The extension to the existing indication for FOSRENOL provides nephrologists in the EU with an important additional option to help tackle the challenge of uncontrolled phosphate at an earlier stage in the progression of kidney disease, before the need for dialysis treatment."

"This is an important development in helping CKD patients better manage their elevated phosphate and we are pleased that FOSRENOL is now approved as a treatment option for these patients in the EU," said Gian Piero Reverberi, Senior Vice President, International Specialty Pharmaceuticals, Shire. "We are firmly committed to serving the needs of renal patients and ensuring that FOSRENOL is available to the prescribers and patients who can benefit from it."

In relation to the US, Shire continues to evaluate its options for securing a label extension to include CKD patients not on dialysis.

    Notes to Editors

    ABOUT FOSRENOL(R) (lanthanum carbonate)

    FOSRENOL is indicated:

    - In the EU as a phosphate binding agent for use in the control of
      hyperphosphataemia in chronic renal failure patients on haemodialysis
      or continuous ambulatory peritoneal dialysis. FOSRENOL is also
      indicated in adult patients with chronic kidney disease not on dialysis
      with serum phosphate levels greater than or equal to 1.78 mmol/L in
      whom a low phosphate diet alone is insufficient to control serum
      phosphate levels.(1)

    - In the US to reduce serum phosphate in patients with end stage renal

    - FOSRENOL is not available in all countries and prescribing information
      may differ between countries. Please consult your local prescribing

    - FOSRENOL works by binding to dietary phosphate in the GI tract; once
      bound, the lanthanum/phosphate complex cannot pass through the
      intestinal lining into the blood stream and is eliminated from the
      body.(1) As a consequence, overall phosphate absorption from the diet
      is decreased.

    - FOSRENOL is available in a broad range of dosage strengths including
      500mg, 750mg, and 1000mg tablets1 which facilitates an effective dosing
      regimen of one tablet per meal for the majority of patients.

    - FOSRENOL was first approved in Sweden in March 2004, and by the US FDA
      in October 2004. FOSRENOL was subsequently approved in all EU markets
      by the European Mutual Recognition Procedure and is now launched in 37
      markets worldwide. It continues to be approved and made available in
      new markets around the world.

    Important Safety Information

    - Patients with renal insufficiency may develop hypocalcaemia. Serum
      calcium levels should therefore be monitored at regular time intervals
      for this patient population and appropriate supplements given.

    - No data are available in patients with severe hepatic impairment.
      Caution should, therefore, be exercised in these patients, as
      elimination of absorbed lanthanum may be reduced.

    - FOSRENOL should not be used during pregnancy.

    - Patients with acute peptic ulcer, ulcerative colitis, Crohn's disease
      or bowel obstruction were not included in clinical studies with

    - The most commonly reported Adverse Drug Reactions are gastrointestinal
      reactions, such as abdominal pain, constipation, diarrhoea, dyspepsia,
      flatulence, nausea and vomiting. These are minimized by taking FOSRENOL
      with food and generally abate with time with continued dosing.
      Hypocalcaemia was the only other commonly reported adverse reaction.
      Full prescribing information is available on request.

    (1) Shire plc. FOSRENOL EU SmPC. Last revised September 2009.
    (2) Shire plc. FOSRENOL US PIL. Last revised April 2008.

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:


Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

SOURCE Shire Plc

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New CapSure™ Cleanroom Wiper from Berkshire Corporation Captures and Retains 42 Times More Contaminant Particles
2. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
3. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
4. Shire Initiates Two Adult ADHD Outreach Programs
5. Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
6. Doctors in New Hampshire Now Treating Cancer with Non-Invasive Image-Guided Radiosurgery Using Novalis Tx(TM) Technology
7. The Crohns & Colitis Foundation of America and Shire Launch Virtual IBD March on the Hill to Increase Funding for Digestive Disease Research
8. Shire begins the year with a strong performance
9. Shire plc: Results of the Annual General Meeting Held on April 28, 2009
10. Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009
11. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
Post Your Comments:
(Date:10/8/2015)... Maryland , October 8, 2015 ... .   --> Goldman Small ... in the small cap and microcap sectors, announced ... research report on PharmaCyte Biotech, Inc. (OTCQB - ... focused on developing and preparing treatments for cancer ...
(Date:10/8/2015)... , Oct. 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, today ... partnering meetings taking place in the month of October: ... Partnering Forum RepliCel will be presenting at the ... on the Mesa to be held October 7-9 in ...
(Date:10/8/2015)... Claremont, CA (PRWEB) , ... October 08, 2015 ... ... by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and results ... abnormally viscous and sticky mucus accumulates in the lungs. This mucus is very ...
(Date:10/7/2015)... , Oct. 7, 2015  ChromaDex Corp. ... and nutritional ingredients that creates science-based solutions for ... nutrition, and pharmaceutical products, today announced that the ... CEO and Founder, is now available for on-demand ... -->   --> ...
Breaking Biology Technology:
... form of skin cancer, afflicts more than 50,000 people in ... rise. In a study published online in Genome ... ever before into the RNA world of the melanoma tumor ... the disease. The latest high-throughput DNA sequencing ...
... ... ... ... ...
... ... report on Fermenters market. The US market for fermenters is projected to reach $180 million ... biological drugs worldwide, and growing use of disposable or single-use fermenters. , ... San Jose, California (PRWEB) February 22, 2010 -- ...
Cached Biology Technology:
(Date:10/7/2015)... Sweden , October 8, 2015 ... the revenues for Fingerprint Cards (FPC) during third quarter 2015 ... revenue guidance of around 860 MSEK that was communicated 20 ... Considering a further strengthened delivery capacity and a continued growing ... quarter 2015 is estimated to be higher than during the ...
(Date:10/2/2015)... 02 2015 ... "Enforcing the Law Using Biometrics" report to ... announced the addition of the "Enforcing the ... --> Research and Markets ( ... "Enforcing the Law Using Biometrics" report to ...
(Date:9/29/2015)... -- News facts: , ... , Minimized design shrinks PC footprint , ... embedded Fujitsu PalmSecure authentication enable enterprises to realize benefits ... that good things come in small packages, with the ... desktop and mobile portfolio. Featuring workplace design that favors ...
Breaking Biology News(10 mins):
... that the clouded leopard found on the islands of Borneo ... secretive rainforest animal was originally thought to be the same ... , Genetic analysis conducted at the U.S. National Cancer ... species is comparable to the differences between other large cat ...
... Professor of Medicine and Pharmacology at the University of ... about 265 twin pairs over the past few years, ... "By studying many traits and genes, we have started ... Studying genetic variations in twins provides scientists with data ...
... in stem cell research may mean big things for cancer ... research team at the University of Kentucky published their findings ... The researchers genetically mapped a stem cell gene and its ... investigation all the way through to the identification of the ...
Cached Biology News:
... human XAB2 (amino terminus) XAB2 (XPA-binding ... interaction with XPA. Immunoprecipitation experiments have also ... with the transcription-coupled repair-specific proteins CSA and ... II. Microinjection experiments with XAB2 antibodies resulted ...
... maintenance, calibration, and validation (MCV) ... 96-well plate used for hands-free ... procedures using the Bio-Plex suspension ... is for use with Bio-Plex ...
Biology Products: